Devics Disease News Today

The use of the monoclonal antibody satralizumab for the long-term treatment of neuromyelitis optica spectrum disorder provides sustained freedom from relapse with no new safety concerns over 5 years.

Breastfeeding by women with MS or NMSOD who are taking anti-CD20 IgG1 monoclonal antibodies appears to be safe for infants, new research suggests.

B cell depletion can last well past the 6-month dosing regimen typically used with ocrelizumab or rituximab for multiple sclerosis or neuromyelitis optica spectrum disorders, new research suggests.

Judy Huber of Greensburg had a vision three decades ago. It was that people with any kind of challenges — physical, emotional or spiritual — could come together in fellowship